US 11,890,385 B2
Biomedical foam
Johannes Jacobus Jacobs, Cork (IE); and Colin Stanley, Crosshaven (IE)
Assigned to Stryker European Operations Holdings LLC, Kalamazoo, MI (US)
Appl. No. 16/955,437
Filed by Stryker European Holdings I, LLC, Kalamazoo, MI (US)
PCT Filed Dec. 20, 2018, PCT No. PCT/IB2018/060463
§ 371(c)(1), (2) Date Jun. 18, 2020,
PCT Pub. No. WO2019/123389, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/608,256, filed on Dec. 20, 2017.
Prior Publication US 2021/0121598 A1, Apr. 29, 2021
Int. Cl. A61L 15/42 (2006.01); A61L 15/26 (2006.01); A61L 15/44 (2006.01)
CPC A61L 15/425 (2013.01) [A61L 15/26 (2013.01); A61L 15/44 (2013.01); A61L 2300/232 (2013.01); A61L 2300/418 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A foam nasal dressing for topically administering a drug to a nasal cavity and for absorbing fluid discharge, the nasal dressing comprising:
a foamed core portion comprising a first polyurethane, the foamed core portion including amorphous segments and crystalline segments, and a hemostatic agent;
a foamed shell portion arranged such that the foamed core portion is disposed within the foamed shell portion, the foamed shell portion having a porosity of greater than 80% and comprising a second polyurethane, the foamed shell portion including amorphous segments and crystalline segments, wherein the first and second polyurethanes are the same or different;
a drug disposed in the foamed shell portion;
the nasal dressing having an elongate shape extending from a first end to a second end, the nasal dressing having a first half adjacent the first end and a second half adjacent the second end; and
a foamed base portion at the second end with the foamed shell portion and the foamed core portion extending from the foamed base portion towards the first end, such that the foamed base portion and the foamed shell portion cooperate to encapsulate the foamed core portion and define an outer surface of the nasal dressing;
wherein a weight of the drug in the first half of the foam nasal dressing is greater than a weight of the drug in the second half of the foam nasal dressing; and wherein the foamed base portion comprises the first polyurethane and is integral with the foamed core portion.